The Phase 1b/2a study will assess the safety of CNP-103 in adults (aged 18-35) and pediatrics (aged 12-17) who have Stage III or newly diagnosed (within the last 6 months) T1D as well as C-peptide ...
The Protein Sequencing Companytm, announces the formation of its Scientific Advisory Board. Comprised of distinguished experts in proteomics, genomics, bioinformatics, chemistry, ...
Financing led by CARMA FUND and RV Invest with participation of High-Tech Gründerfonds and othersAkribion is pioneering a unique, RNA-guided, nuclease-based technology for programmable cell ...
retriever generates disease-specific transcriptional drug response signatures by merging transcriptional signatures over time, concentration, and cell-type. These signatures can then be matched to ...